The price of Roivant Sciences Ltd (NASDAQ:ROIV) shares last traded on Wall Street fell -1.31% to $11.32.
ROIV stock price is now 5.15% away from the 50-day moving average and 0.58% away from the 200-day moving average. The market capitalization of the company currently stands at $7.70B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Ramaswamy Vivek, 10% Owner sold 547,430 shares of the company’s stock on Jun 04 ’25. The stock was sold for $6,207,856 at an average price of $11.34. Upon completion of the transaction, the 10% Owner now directly owns 38,627,181 shares in the company, valued at $437.26 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 06 ’25, 10% Owner Ramaswamy Vivek sold 200,800 shares of the business’s stock. A total of $2,246,952 was realized by selling the stock at an average price of $11.19. This leaves the insider owning 38,426,381 shares of the company worth $434.99 million. A total of 38.51% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $8.73 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 33.47, and a quick ratio of 33.47. The fifty day moving average price for ROIV is $10.7657 and a two-hundred day moving average price translates $11.254425 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for 2025-03-31. The net profit margin was -225.71% and return on equity was -8.56% for ROIV. The company reported revenue of -$39.57 million for the quarter, compared to -$8.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 387.28 percent.